Osteoarthritis (OA) is also known as osteoarthrosis, senile arthritis, degenerative arthritis, and hypertrophic arthritis. Osteoarthritis is a chronic joint disease characterized by articular cartilage degeneration and secondary bone hyperplasia. Other features include progressive cartilage degradation, subchondral bone reconstruction, loss of joint space, formation of marginal callus, and loss of joint function. The disease is more common among middle-aged and older populations, and the number of female patients is bigger than male patients. Articular cartilage lesions and synovial lesions, joint swelling, and joint deformities are main causes for restricted activity of the elderly.
Studies found that BMSCs with strong immunomodulatory and anti-inflammatory effects can regulate local environment, activate endogenous progenitor cells, secret various factors, repair damaged tissues, improve joint micro-environment and finally restore joint functions through interaction between cells. These properties make BMSCs an ideal treatment for osteoarthritis.
BMSCs produced by Stemedica are ischemic tolerance MSCs (itMSCs) with strong inflammatory response-inhibitory effects. A clinical trial using itMSCs to treat osteoarthritis in Mexico have been approved by Mexico’s FDA equivalent COFEPRIS; subjects will receive a single intra-articular dose of 1.5x107human allogeneic bone marrow mesenchymal stem cells. The study has now enrolled more than 160 patients, most of whom responded well to the treatment.